Physician profile
John H Lee
NPI 1568637361
$3,760.18
in general payments reported to CMS, 2019-2025
23 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $791 · 2021: $459 · 2022: $438 · 2023: $538 · 2024: $565 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,600.61 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Aerie Pharmaceuticals, INC. | $354.99 | 2019-2021 | |
| Abbvie INC. | $322.45 | 2023-2025 | |
| Sight Sciences, INC. | $258.00 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $255.06 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $201.12 | 2022-2025 | Miebo, Vyzulta, Lotemax Sm |
| Harrow Eye, LLC | $101.93 | 2024 | Vevye |
| Glaukos Corporation | $101.26 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $78.32 | 2022-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $63.60 | 2020-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $61.78 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $60.17 | 2021-2025 | Oxervate |
| Horizon Therapeutics Plc | $56.90 | 2022-2023 | Tepezza |
| Ivantis, INC | $49.25 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $37.04 | 2022-2023 | Tobradex St |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $27.56 | 2019 | |
| Oyster Point Pharma, INC. | $26.60 | 2022 | |
| Kala Pharmaceuticals, INC. | $21.33 | 2021 | |
| Thea Pharma INC. | $20.29 | 2023 | Iyuzeh |
| New World Medical,INC. | $18.12 | 2019 | |
| Amgen INC. | $16.63 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $14.43 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.